Athira Pharma announces name change to LeonaBio

Athira Pharma (ATHA) has changed its name to LeonaBio (LONA), Inc. The name change aligns with the Company’s transformative acquisition of rights to develop and commercialize lasofoxifene, a promising late-stage clinical asset for the potential treatment of metastatic breast cancer, currently in a Phase 3 trial. In connection with the name change, the Company will change its ticker symbol to “LONA.” The Company’s common stock will commence trading on The Nasdaq Capital Market under the new ticker symbol on January 12, 2026. “This marks an exciting and transformative period for our company and emphasizes our commitment to advancing a pipeline of innovative, late-stage assets both internally developed and strategically in-licensed with the goal of accelerating their path to market and maximizing their potential clinical and commercial impact,” said Mark Litton, CEO. “At LeonaBio, we are building a pipeline with the potential to change lives and create enduring value. Our new name truly reflects our commitment to leadership, resilience, and innovation-qualities that define our expanded mission to deliver transformative therapies for patients battling diseases that need better treatment options.”